The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert)
Abstract
Older patients with AML have poor prognosis after chemotherapy and allo-SCT was historically limited to the young patients. In the multicentre retrospective study we analyzed 96 consecutive AML patients GREATER-THAN OR EQUAL TO 50 years allografted with related (n=59) or unrelated (n=37) donor.
The 2- year OS and DFS rates were 45 % and 42 % for the whole group. The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p = 0,896).
The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts. Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011).
Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0.009) were also the only independent variables associated with inferior DFS. In conclusion, our analysis indicates that outcomes of allografted AML patients aged GREATER-THAN OR EQUAL TO 50 years are determined by cytogenetic risk category and disease status at transplantation and not by the type of donor.